These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 21406411

  • 1. Lupus anticoagulant interference in activated protein C resistance testing: in vitro phenomenon or in vivo pathophysiologic effect?
    Shen YM, Cimo ML, Bai Y, Frenkel E, Sarode R.
    Clin Appl Thromb Hemost; 2011; 17(6):E190-5. PubMed ID: 21406411
    [Abstract] [Full Text] [Related]

  • 2. Determination of activated protein C resistance in anticoagulated and lupus positive patients.
    Ivey LM, Thom JY, Ivey JG, Baker RI.
    Blood Coagul Fibrinolysis; 2000 Jul; 11(5):439-45. PubMed ID: 10937805
    [Abstract] [Full Text] [Related]

  • 3. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
    Gessoni G, Valverde S.
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
    [Abstract] [Full Text] [Related]

  • 4. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B.
    Semin Thromb Hemost; 1999 Oct; 25(3):273-89. PubMed ID: 10443959
    [Abstract] [Full Text] [Related]

  • 5. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
    Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter C.
    Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
    [Abstract] [Full Text] [Related]

  • 6. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies.
    Viveros ME, Cabiedes J, Reyes E, Cabral AR.
    Rev Invest Clin; 2005 Feb; 57(4):563-71. PubMed ID: 16315641
    [Abstract] [Full Text] [Related]

  • 7. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
    Wilmer M, Stocker C, Bühler B, Conell B, Calatzis A.
    Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
    [Abstract] [Full Text] [Related]

  • 8. Acquired activated protein C resistance caused by lupus anticoagulants.
    Saenz AJ, Johnson NV, Van Cott EM.
    Am J Clin Pathol; 2011 Sep; 136(3):344-9. PubMed ID: 21846908
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Coagulation factor V and thrombophilia: background and mechanisms.
    Segers K, Dahlbäck B, Nicolaes GA.
    Thromb Haemost; 2007 Sep; 98(3):530-42. PubMed ID: 17849041
    [Abstract] [Full Text] [Related]

  • 11. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B, Castoldi E, Mahler A, Hanel D, Müller J, Hamedani NS, Biswas A, Oldenburg J, Pavlova A.
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [Abstract] [Full Text] [Related]

  • 12. [Analysis of phenotype resistance to activated protein C (APC resistance)].
    Hudecek J, Ivanková J, Dobrotová M, Hybenová J, Pullmann R, Kubisz P.
    Vnitr Lek; 1999 Dec; 45(12):723-8. PubMed ID: 10951849
    [Abstract] [Full Text] [Related]

  • 13. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P, Scudeller A, Radossi P, Gavasso S, Girolami B, Tormene D, Girolami A.
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [Abstract] [Full Text] [Related]

  • 14. Activated protein C resistance assay detects thrombotic risk factors other than factor V Leiden.
    Graf LL, Welsh CH, Qamar Z, Marlar RA.
    Am J Clin Pathol; 2003 Jan; 119(1):52-60. PubMed ID: 12520697
    [Abstract] [Full Text] [Related]

  • 15. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
    Guasch JF, Lensen RP, Bertina RM.
    Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Maximising the diagnostic potential of APTT-based screening assays for activated protein C resistance.
    Moore GW, Chege E, Culhane AP, Hunt BJ.
    Int J Lab Hematol; 2015 Dec; 37(6):844-52. PubMed ID: 26303324
    [Abstract] [Full Text] [Related]

  • 18. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
    Dahlbäck B.
    Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
    [Abstract] [Full Text] [Related]

  • 19. Detecting APC-resistant factor V: a functional method without plasma dilution.
    Rylatt DB, Hohnen-Behrens C, Pilgrim RL, Dickeson LE, Neal M, Exner T.
    Blood Coagul Fibrinolysis; 1999 Sep; 10(6):359-66. PubMed ID: 10493217
    [Abstract] [Full Text] [Related]

  • 20. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
    Schöni R, Quehenberger P, Wu JR, Wilmer M.
    Thromb Res; 2007 Sep; 119(1):17-26. PubMed ID: 16934314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.